生物靶区定位在胶质瘤术后放射治疗的临床价值研究  

Clinical Value of Biological Target Location in the Postoperative Radiotherapy of Glioma

作　　者：闫文明[1] 王宏伟[1] 郁志龙[1] 宝莹娜[1] 张剑[1] 林宇[1] 

机构地区：[1]内蒙古医科大学附属医院,010050

出　　处：《实用癌症杂志》2016年第8期1349-1351,1354,共4页The Practical Journal of Cancer

摘　　要：目的探讨生物靶区定位在胶质瘤术后放射治疗的临床价值。方法选取术后行放射治疗的脑胶质瘤患者80例,全部经开颅手术或立体活检确诊。将采用^(11)C-蛋氨酸(11C-Met)-PET/MRI融合图像进行放射靶区勾画的44例患者纳入观察组,将仅采用MRI图像勾画放射靶区的36例患者纳入对照组。对比两组患者放疗后的近期疗效,不良反应和远期疗效。结果两组患者LCR差异无统计学意义(P>0.05)。两组患者的CR、PR和PD比较无显著差异(P>0.05),在SD方面差异显著(P<0.05)。观察组患的治疗过程中不良反应发生率低于对照组(P<0.05)。两组患者1、2、3年OS分别为63.6%、43.2%、34.1%和58.3%、36.1%、27.8%,差异有统计学意义(P<0.05)。生存曲线表明观察组的预后优于对照组。结论生物靶区定位用于胶质瘤术后放射治疗不良反应发生率低,可以明显提高患者的预后,值得临床推广使用。Objective To explore the clinical value of biological target location in the postoperative radiotherapy of glio- ma. Methods 80 eases of brain glioma patients were treated with radiotherapy. All patients were confirmed by craniotomy or ster- eotactic biopsy. 44 patients used ^11C-methionine （^11 C-Met）-PET/MRI image fusion radiation target delineation made was the study group and 36 patients used only MRI images in the radiation target area was the control group. Short-term efficacy,long-term efficacy and adverse reactions after radiotherapy of the 2 group were compared. Results There was no significant difference in LCR between the 2 groups （P 〉 0.05 ）. There was no significant difference in PD, PR and CR between the 2 groups （P 〉 0.05 ） , and the difference was significant （P 〈 0.05） in SD. The adverse reactions in the observation group was less than that of the con- trol group （P 〈0.05）. 1-,2-,and 3-year OS of the 2 groups were 63.6% ,43.2% ,34.1% and 58.3% ,36.1% ,27.8% ,and the difference was statistically significant （ P 〈 0.05 ）. Survival curves showed that the prognosis of the observation group was superior to the control group. Conclusion Biological target position for postoperative radiotherapy has low adverse reactions, and it can significantly improve the prognosis of patients, it is worthy of clinical use.

关 键 词：生物靶区 胶质瘤 放射治疗 

分 类 号：R730.264[医药卫生—肿瘤]